Evaluation of alterations in hemodynamic indices and brain natriuretic peptide (BNP) concentration was carried in response to levosimendan infusion. 77 patients with chronic heart failure were included in the study. Levosimendan (Simdax, Orion Pharma) showed statistically significant increase in ejection fraction, stroke and end systolic left ventricular volume, decreased pulmonary arterial pressure and BNP concentration. According to results of drug administration patients can be divided into groups depending on different response to therapy. Good effect of the drug in dynamics of pulmonary arterial pressure, ejection fraction and BNP concentration was observed accordingly in 14.5%, 13.4% and 7.6% of patients. Moderate alterations of these parameters were observed accordingly in 79, 64.2 and 45.5% of patients. Accordingly in 6.5, 22.4 and 47 % of patients parameters didn't virtually change. It is shown that dynamics in pulmonary arterial pressure best reflects the direct effect of the drug. More significant effect of the drug in patients with moderate heart failure recommends earlier start of treatment. Levosimendan can be used as a pharmacologic test allowing estimating the prognosis and surgical tactics.